DPP4 Inhibition Transcriptomic Data in hiPSC-Derived Steatotic Hepatocyte-Like Cells

Christiane Loerch published a research data sheet on figshare in March 2026. The 2.7 MB PDF contains transcriptomic analysis results from a human induced pluripotent stem cell (hiPSC)-derived hepatocyte-like cell (HLC) model of metabolic dysfunction-associated steatotic liver disease (MAFLD). The data explores the effects of DPP4 inhibition by vildagliptin on metabolism and inflammation-associated pathways.

Use Cases

• Analyzing transcriptomic changes associated with steatosis induction based on oleic acid feeding described in the methods.
• Studying the molecular impact of DPP4 inhibition on disease pathways based on the analysis of vildagliptin-treated cells.
• Investigating the role of DPP4 in inflammation and metabolism pathways relevant to MAFLD as discussed in the results.

Strengths

• Data is associated with a specific, peer-reviewed research methodology using hiPSC-derived hepatocyte-like cells and NGS-based transcriptomics.
• The dataset is openly available under a CC-BY-4.0 license, permitting reuse with attribution.
• Platform tags provide specific keywords linking to relevant biological concepts and drugs.

Limitations

• The primary data format is a PDF (2.7 MB), which may require extraction or manual inspection to access underlying numerical data.
• Column-level documentation and sample data are unavailable, making field semantics and structure unclear before download.
• Row count is unknown, which may limit suitability assessment for computational analysis.

Provenance

Source

Christiane Loerch via figshare.

Collection Method

Generated from an in vitro pluripotent stem cell-based model; NGS-based global transcriptomic analyses were performed on steatotic HLCs with and without DPP4 inhibitor vildagliptin.

Time Range

null

Freshness

Last updated 2026-03-18 07:43:59.

Geography

null